The aim of this case study was to evaluate the introduction of a health technology, the enoxaparin 40 mg, for prolonged thrombosis prophylaxis in cancer patients submitted to surgical procedures in Brazilian socioeconomic policies. Before the case study, due to lack of a Brazilian model of evaluation of health technologies. A review was made in this subject to create the frame used in the case study. The study create two Markov models to simulate the evolution of the patients using enoxaparin 40 mg for prophylaxis versus the control group, during a period of 2 years. The benefits inputs were obtained with a literature review, the treatment cost were developed with the help of professionals of the Brazilian National institute of Cancer (INCA). The study result show that the use of enoxaparin 40 mg when compared with no prophylaxis is a dominant treatment as it offers greater health benefits at lower cost.